HSA
ALXN

HBK Sorce Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

HBK Sorce Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,685
Closed -$235K – 281
2016
Q1 		$235K Buy
+1,685
New +$247K 0.06% 215

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HBK Sorce Advisory's ALXN Position: Q2 2016 in Review

HBK Sorce Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,685 shares — an estimated $235K sold.

HBK Sorce Advisory first reported a position in ALXN in Q1 2016 and held it in 1 quarter. The position peaked at $235K in Q1 2016. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • HBK Sorce Advisory reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • HBK Sorce Advisory sold 1,685 Alexion Pharmaceuticals shares in Q2 2016, an estimated $235K.
  • HBK Sorce Advisory first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • HBK Sorce Advisory's Alexion Pharmaceuticals position peaked at $235K in Q1 2016.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on HBK Sorce Advisory's 13F filing for Q2 2016, filed 12 Aug 2016.